EP1212065A4 - Zusammenstellungen und methoden zur erhöhung des hdl cholesterolspiegels - Google Patents

Zusammenstellungen und methoden zur erhöhung des hdl cholesterolspiegels

Info

Publication number
EP1212065A4
EP1212065A4 EP00947080A EP00947080A EP1212065A4 EP 1212065 A4 EP1212065 A4 EP 1212065A4 EP 00947080 A EP00947080 A EP 00947080A EP 00947080 A EP00947080 A EP 00947080A EP 1212065 A4 EP1212065 A4 EP 1212065A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
cholesterol levels
hdl cholesterol
raising hdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00947080A
Other languages
English (en)
French (fr)
Other versions
EP1212065A1 (de
Inventor
Bei Shan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of EP1212065A1 publication Critical patent/EP1212065A1/de
Publication of EP1212065A4 publication Critical patent/EP1212065A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00947080A 1999-07-08 2000-07-07 Zusammenstellungen und methoden zur erhöhung des hdl cholesterolspiegels Withdrawn EP1212065A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US612135 1990-11-13
US14299499P 1999-07-08 1999-07-08
US142994P 1999-07-08
US61213500A 2000-07-07 2000-07-07
PCT/US2000/018533 WO2001003705A1 (en) 1999-07-08 2000-07-07 Compositions and methods for raising hdl cholesterol levels

Publications (2)

Publication Number Publication Date
EP1212065A1 EP1212065A1 (de) 2002-06-12
EP1212065A4 true EP1212065A4 (de) 2004-02-11

Family

ID=26840588

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00947080A Withdrawn EP1212065A4 (de) 1999-07-08 2000-07-07 Zusammenstellungen und methoden zur erhöhung des hdl cholesterolspiegels

Country Status (5)

Country Link
EP (1) EP1212065A4 (de)
JP (1) JP2004500332A (de)
AU (1) AU6074700A (de)
CA (1) CA2377999A1 (de)
WO (1) WO2001003705A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
AU1291901A (en) * 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels
US20020048572A1 (en) * 2000-05-03 2002-04-25 Bei Shan Treatment of hypertriglyceridemia and other conditions using LXR modulators
CN101596191B (zh) 2001-01-26 2011-06-15 中外制药株式会社 用作代谢调节剂的丙二酰基辅酶a脱羧酶抑制剂
ES2274005T3 (es) 2001-01-26 2007-05-16 Chugai Seiyaku Kabushiki Kaisha Inhibidores de malonyl-coa decarboxilasa usados como moduladores metabolicos.
ES2284817T3 (es) * 2001-01-26 2007-11-16 Chugai Seiyaku Kabushiki Kaisha Procedimientos para el tratamiento de enfermedades con inhibidores de la malonil coa descarboxilasa.
BR0207408A (pt) 2001-02-20 2004-02-25 Chugai Pharmaceutical Co Ltd Azóis como inibidores de malonil-coa decarboxilase úteis como moduladores metabólicos
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
AU2002304826A1 (en) * 2001-03-01 2002-10-08 Lion Bioscience Ag Cofactors of the liver x receptor alpha and methods of use
CA2444028A1 (en) 2001-04-18 2002-10-31 Genzyme Corporation Methods of treating syndrome x with aliphatic polyamines
WO2003018047A2 (en) * 2001-08-20 2003-03-06 Zlb Bioplasma Ag Hdl for the treatment of stroke and other ischemic conditions
EP1285662A1 (de) * 2001-08-20 2003-02-26 ZLB Bioplasma AG Rekonstituiertes High-Density -Lipoprotein zur Behandlung von Schlaganfällen und Ischämiezuständen
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
GB2381866A (en) * 2001-11-12 2003-05-14 Karobio Ab Assays for liver X receptor (LXR) modulators
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1511483A4 (de) * 2002-03-27 2009-03-18 Smithkline Beecham Corp Verfahren zur behandlung mit lxr-modulatoren
AU2003223684A1 (en) * 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Lxr modulators for the treatment of cardiovascular diseases
AU2003228614A1 (en) * 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Lxr modulators
GB0316237D0 (en) * 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) * 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
EP1646394A2 (de) * 2003-07-22 2006-04-19 Glaxo Group Limited Behandlungsverfahren mit lxr-agonisten
ATE400272T1 (de) 2003-08-01 2008-07-15 Chugai Pharmaceutical Co Ltd Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer
ES2353306T3 (es) 2003-08-01 2011-03-01 Chugai Seiyaku Kabushiki Kaisha Compuestos heterocíclicos útiles como inhibidores de la malonil-coa-descarboxilasa.
EP1658071B1 (de) 2003-08-01 2008-09-10 Chugai Seiyaku Kabushiki Kaisha Azol-verbindungen auf cyanoguanidin-basis als malonyl-coa decarboxylase-hemmer
JP4727579B2 (ja) 2003-08-01 2011-07-20 中外製薬株式会社 マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なシアノアミド化合物
CA2592771A1 (en) 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
SE0500056D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
US20090029945A2 (en) * 2005-01-10 2009-01-29 Astrazeneca Ab Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
CA2615718A1 (en) 2005-07-22 2007-02-01 Amgen Inc. Aniline sulfonamide derivatives and their uses
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
BR112013005425A2 (pt) 2010-09-07 2018-05-02 Snu R&Db Foundation compostos sesterterpenos e suas utilizações
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
CN105250253B (zh) * 2015-10-30 2018-06-26 黄恺 T0901317作为parp1抑制剂的应用
EA034514B1 (ru) 2015-12-15 2020-02-14 Астразенека Аб Изоиндольные соединения
EP3638661A1 (de) 2017-06-14 2020-04-22 Astrazeneca AB Als ror-gamma-modulatoren verwendbare 2,3-dihydroisoindol-1-carboxamide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034461A2 (en) * 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions and methods of modulating cholesterol metabolism
WO2000054759A2 (en) * 1999-03-15 2000-09-21 Tularik Inc. Lxr modulators
WO2000078972A2 (en) * 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Regulation with binding cassette transporter protein abc1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES442992A1 (es) * 1974-12-02 1977-08-01 Scherico Ltd Un procedimiento para preparar 2-anilino-oxazolinas.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034461A2 (en) * 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions and methods of modulating cholesterol metabolism
WO2000054759A2 (en) * 1999-03-15 2000-09-21 Tularik Inc. Lxr modulators
WO2000078972A2 (en) * 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Regulation with binding cassette transporter protein abc1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO0103705A1 *
YOUNG S G ET AL: "THE ABCS OF CHOLESTEROL EFFLUX", NATURE GENETICS, NEW YORK, NY, US, vol. 22, no. 4, August 1999 (1999-08-01), pages 316 - 318, XP000889764, ISSN: 1061-4036 *

Also Published As

Publication number Publication date
JP2004500332A (ja) 2004-01-08
EP1212065A1 (de) 2002-06-12
WO2001003705A1 (en) 2001-01-18
CA2377999A1 (en) 2001-01-18
AU6074700A (en) 2001-01-30

Similar Documents

Publication Publication Date Title
EP1212065A4 (de) Zusammenstellungen und methoden zur erhöhung des hdl cholesterolspiegels
NZ514350A (en) Compositions and methods for effecting the levels of cholesterol
IL140989A0 (en) Compositions and methods for treating osteoporosis and lowering cholesterol
AU2001245401A1 (en) Hydrazones and analogs as cholesterol lowering agents
EP1176948A4 (de) Anti-nausea zusammensetzungen und methoden
AU1856997A (en) Method for raising hdl cholesterol levels
GB0121314D0 (en) β-Secretase enzyme compositions and methods
AUPQ419099A0 (en) Novel compositions and methods
GB2348808B (en) Methods and compositions for desensitisation
AU3877900A (en) Compositions and methods for preventing and treating sexual dysfunctions
GB9920678D0 (en) Sanitising compositions and methods
AU4215901A (en) Methods and compositions for immunoregulation
IL149715A0 (en) MICROBIAL 9α-HYDROXYLATION OF STEROIDS
IL139386A0 (en) Dhea composition and method
AU6094200A (en) Nor gene compositions and methods for use thereof
AU2001261513A1 (en) Composition and method for increasing testosterone levels
EP1207896A4 (de) Verfahren und zusammensetzungen zur reduzierung des serumphosphatspiegels
EP1163340A4 (de) Verbindungen und verfahren zur änderung der genexpression
AU2003257051A8 (en) Composition and method for lowering cholesterol
GB0318107D0 (en) ›-Secretase enzyme compositions and methods
AU5474400A (en) Compositions and methods for targeted gene insertion
AU1477601A (en) Genetic compositions and methods
AU5931300A (en) Ringene compositions and methods for use thereof
AU7597400A (en) Methods and compositions utilizing rad51
HUP0100613A3 (en) Methods and compositions for stabilizing acetylcholine compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020112;LT PAYMENT 20020112;LV PAYMENT 20020112;MK PAYMENT 20020112;RO PAYMENT 20020112;SI PAYMENT 20020112

A4 Supplementary search report drawn up and despatched

Effective date: 20040102

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 3/06 B

Ipc: 7A 61K 31/18 A

17Q First examination report despatched

Effective date: 20040423

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060201